Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 19/20 | 0.63 |
| ▸ | BTK | Q06187 | 16/20 | 0.63 |
| ▸ | LCK | P06239 | 15/20 | 0.63 |
| ▸ | EGFR | P00533 | 8/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21855166 | 1.00 | JAK3 (0.63) | JAK3BTKLCKEGFR | |
| SCHEMBL21855199 | 0.85 | JAK3 (0.63) | JAK3BTKLCKEGFR | |
| SCHEMBL28653131 | 0.85 | JAK3 (0.63) | JAK3BTKLCKEGFR | |
| SCHEMBL31039883 | 0.85 | JAK3 (0.63) | JAK3BTKLCKEGFR | |
| SCHEMBL21946806 | 0.85 | JAK3 (0.72) | JAK3BTKLCKEGFR | |
| SCHEMBL21855216 | 0.85 | JAK3 (0.72) | JAK3BTKLCKEGFR | |
| SCHEMBL21946809 | 0.85 | JAK3 (0.72) | JAK3BTKLCKEGFR | |
| SCHEMBL21946759 | 0.84 | JAK3 (0.64) | JAK3BTKLCKEGFR | |
| SCHEMBL31039901 | 0.84 | JAK3 (0.64) | JAK3BTKLCKEGFR | |
| SCHEMBL21946364 | 0.84 | JAK3 (0.73) | JAK3BTKLCKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118955473-A | Difunctional compounds for degrading BTK via the ubiquitin proteasome pathway | 紐力克斯治疗公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-113412259-B | Difunctional compounds for degrading BTK via the ubiquitin proteasome pathway | 紐力克斯治疗公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| CN-113412259-A | Bifunctional compounds for the degradation of BTK via the ubiquitin proteasome pathway | 紐力克斯治疗公司 | 2021-09-17 | — | — | CN | disclosed |
| WO-2020081450-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | JAK3 623/4885BTK 3/4885LCK 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.